Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.42 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303101 | 1.00 | GPR139 (0.44) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL22952815 | 0.92 | KDM4E (0.40) | GPR139LMNAMAPK1KDM4E | |
| SCHEMBL22965257 | 0.92 | KDM4E (0.40) | GPR139LMNAMAPK1KDM4E | |
| SCHEMBL21303102 | 0.89 | GPR139 (0.45) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL21288077 | 0.89 | GPR139 (0.45) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL21272738 | 0.87 | GPR139 (0.44) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL21272741 | 0.87 | GPR139 (0.44) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL29589628 | 0.87 | GPR139 (0.44) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL22953247 | 0.87 | GPR139 (0.44) | GPR139ITGB3ITGAVITGB5ITGB6 | |
| SCHEMBL21288075 | 0.86 | PDE2A (0.48) | GPR139ITGB3ITGAVITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | GPR139 663/4885ITGB3 2840/4885ITGAV 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.